Induction of Labor - Comparison Propess with Prostaglandin E2 Vaginal Gel and Balloon Catheter

NCT ID: NCT06803992

Last Updated: 2025-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-29

Study Completion Date

2027-01-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

One of every four births in the Western world is induced, usually due to the risk of maternal and fetal morbidity. There are several methods of labor induction, pharmacological and mechanical. In cases of unfavorable cervix (Bishop score is below 5), cervical ripening can be induced by either prostaglandins E2 (slow release 10 mg dinoprostone insert (propess) or vaginal gel 1-2 mg) or mechanically by Foley catheter balloon (FCB).

The efficacy of labor induction of propess versus vaginal gel combined with FCB was not studied previously.

The goal of this randomized controlled trial is to compare the efficacy of propess versus PGE2 vaginal gel combined with FCB in women with singletons undergoing labor induction at term. The main question it aims to answer is to compare the time from the beginning of labor induction until delivery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Induction of Labor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel Assignment
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Propess pessary

Placement of a slow-release 10 mg dinoprostone insert (propess) in the posterior fornix for up to 24 hours until labor initiation or favorable cervix, followed by amniotomy and oxytocin administration. In a case of failure, induction of labor will be done with either PGE2 gel and/or Foley catheter.

Group Type EXPERIMENTAL

Dinoprostone vaginal insert

Intervention Type DRUG

Described in the arm descriptions

Sequential PGE2 vaginal gel and Foley catheter balloon

Insertion of 1 mg dinoprostone (PGE2) vaginal gel to the posterior fornix with reassessment up to 6 hours later. If the Bishop score is still less than 5 and there are no more than 4 contractions in 20 minutes of monitoring, an additional PGE2 vaginal gel of 2 mg is inserted. If there are more than 4 contractions in 20 minutes of monitoring or if after up to 6 hours there will be low Bishop score, a 60 ml Foley catheter balloon is placed for 6 to 12 hours or until spontaneous expulsion. When the cervix is favorable, amniotomy and oxytocin administration are followed.

In a case of a failure, induction of labor with Propess will be conducted.

Group Type EXPERIMENTAL

Dinoprostone gel and Foley catheter balloon

Intervention Type COMBINATION_PRODUCT

Described in the arm descriptions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dinoprostone vaginal insert

Described in the arm descriptions

Intervention Type DRUG

Dinoprostone gel and Foley catheter balloon

Described in the arm descriptions

Intervention Type COMBINATION_PRODUCT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Propess

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women at term (37 weeks of gestation or more) with singleton
* pregnancies that are intended for IOL.
* Initial bishop score \<5
* No contraindications to receive either treatment.
* Women who will give informed consent to be included in the study.
* Women at or over the age of 18.

Exclusion Criteria

* Women with a known hypersensitivity or contraindications to Propess / PGE2.
* Parity 5 or more
* Labor contractions more than 4 in 20 min
* Glaucoma
* History of previous uterine surgery
* Hypersensitivity to prostaglandins
* Vaginal delivery is contraindicated
* Active cardiac, renal, pulmonary, or hepatic disease
* Severe asthma or pulmonary disease
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

HaEmek Medical Center, Israel

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zohar Nachum, Professor

Role: STUDY_DIRECTOR

Emek Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Emek medical center

Afula, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zohar Nachum, Professor

Role: CONTACT

Phone: +972547696562

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

79-23

Identifier Type: -

Identifier Source: org_study_id